About
The world’s aging research, the minute it lands.
Every journal, every language. The findings worth your time, in plain words.
AgingResearch.News is the superintelligence for aging research. It weighs what each paper’s own work shows and cites every claim.
Why it exists
More than 8 million research papers came out last year, over 22,000 a day. The work that matters to aging is scattered through all of them: in cardiology and oncology journals, under other words, in other languages. No one can read it all. Good work goes unseen, and weak work travels on its headline. The headline says breakthrough. The paper says mice.
We exist to get the research that could add healthy years to human lives to the people who can build on it, while it can still change what they do next.
How it works
Every new paper. PubMed, bioRxiv, medRxiv, arXiv, Research Square and the journals PubMed misses. Papers in other languages are translated, then judged like the rest.
Judged on its own work. Each paper is asked six questions: how relevant its own work is to aging, what link to aging that work shows, how newsworthy it is, what kind of study it is, what it mainly establishes, and whether it is promotional. No h-index. No impact factor. No famous-lab bonus. An author’s record of misconduct counts against the paper.
Written, then checked against the paper. The papers worth reading become short stories in plain words. Each one says who was studied, as in “Randomized trial in 410 people” or “Experiments in 12 mice,” and names the study’s main limit. A writing model works from the paper’s abstract and, where the paper is open, its methods and results. A judging model scores each part of the story against that text, and a second model reads it for claims the paper does not make. A story that fails either goes back to the writer, and one that still misreports or overstates its paper is not published.
Evidence as it stands, never a grade. Every drug, gene and process has a page: the species its findings reached, whether independent labs found the same and in how many countries, what points the other way, which trials ended with no results posted, and who paid.
Retracted work comes out. More than 74,000 retraction, correction, concern and misconduct notices are checked against every paper. Retracted work leaves every feed, email and answer.
Questions, answered from the papers. Ask AgingResearch.News cites every claim and keeps animal and cell results apart from human ones.
Standards and corrections
Our editor, Boris Djordjevic, answers for these standards and for every correction. A story shown to misreport its paper is corrected or withdrawn: tell us which one.
Our standards in full, the day’s numbers and the last 90 days of outages are on Status. What’s new is on Updates.
Who is behind it
Boris Djordjevic, founder and editor
Boris has worked on longevity since 2011. He studied medicine at the Vrije Universiteit Brussel and was a visiting researcher at University College London. He is founder and CEO of 199 Biotechnologies, which works on partial reprogramming and gene therapies; papers in that field are judged and checked like every other. He has co-authored eight peer-reviewed papers, in journals including Nature Methods, Science Advances and Aging, spoke at the Aging Research and Drug Discovery meeting (ARDD) in 2024, and sits on the board of HEALES, the Healthy Life Extension Society. He is based between London and Singapore.
The company
AgingResearch.News is published by Paperfoot AI Pte. Ltd., registered in Singapore, UEN 202450712K, at 32 Pekin Street, #05-01, Singapore 048762. It opened to readers on October 2, 2026. Research Resource Identifier: RRID:SCR_029124.
Reading is free. Readers and teams who want more pay through Plus, Pro and Enterprise.